左心耳封堵器相关性血栓的预测因素研究进展

马楠; 熊芊卉; 戴凯; 徐佳祥; 宋志芳; 赵健清; 应如

doi:10.13201/j.issn.1001-1439.2024.02.003

左心耳封堵器相关性血栓的预测因素研究进展

- 南昌大学第一附属医院(南昌，330000)
基金项目:
国家自然科学基金项目(No：81960093)

详细信息

通讯作者: 应如，E-mail：yingru2005@163.com

中图分类号: R541.7

收稿日期: 2022-12-18

刊出日期: 2024-02-13

Progresses in predicting factors of left atrial appendage occluder associated thrombosis

- The First Affiliated Hospital of Nanchang University, Nanchang, 330000, China

More Information

Corresponding author: YING Ru, E-mail: yingru2005@163.com

Received Date: 18 December 2022

Publish Date: 13 February 2024

摘要

摘要: 器械相关性血栓(DRT)已被认为是左心耳封堵(LAAO)的重要并发症，与术后卒中发生率增加有关，高龄、缺血性卒中或短暂性脑缺血发作病史、左心耳增大、左心室射血分数降低、非阵发性心房颤动等被认为导致LAAO术后DRT危险性增高，然而关于DRT的预测因素仍然众说纷纭，无统一认识。本文通过分析国内外相关文献，对目前DRT的预测因素作一回顾及评述。
- 经皮左心耳封堵术 /
- 非瓣膜性心房颤动 /
- 器械相关血栓栓塞
Abstract: Device related thrombosis(DRT) has been considered as an important complication of left atrial appendage occlusion(LAAO), and is related to the increased incidence of postoperative stroke. Older age, history of ischemic stroke or transient ischemic attack(TIA), maximum diameter of left atrial appendage, decreased left ventricular ejection fraction(LVEF), non paroxysmal atrial fibrillation are increased risk of DRT after LAAO. However, there are still different opinions on the predictive factors of DRT. This paper reviews the current researches about predictive factors of DRT.
- percutaneous left atrial appendage occlusion /
- non valvular atrial fibrillation /
- device related thrombus

HTML全文

图 1 肺静脉嵴

Figure 1. Pulmonary venous ridge

下载: 全尺寸图片幻灯片

参考文献(60)

[1]	Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation[J]. Ann Thorac Surg, 1996, 61(2): 755-759. doi: 10.1016/0003-4975(95)00887-X
[2]	Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis[J]. J Am Coll Cardiol, 2015, 65(24): 2614-2623. doi: 10.1016/j.jacc.2015.04.025
[3]	Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial[J]. Lancet, 2009, 374(9689): 534-542. doi: 10.1016/S0140-6736(09)61343-X
[4]	Pracon R, Bangalore S, Dzielinska Z, et al. Device thrombosis after percutaneous left atrial appendage occlusion is related to patient and procedural characteristics but not to duration of postimplantation dual antiplatelet therapy[J]. Circ Cardiovasc Interv, 2018, 11(3): e005997. doi: 10.1161/CIRCINTERVENTIONS.117.005997
[5]	Dukkipati SR, Kar S, Holmes DR, et al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes[J]. Circulation, 2018, 138(9): 874-885. doi: 10.1161/CIRCULATIONAHA.118.035090
[6]	Fauchier L, Cinaud A, Brigadeau F, et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation[J]. J Am Coll Cardiol, 2018, 71(14): 1528-1536. doi: 10.1016/j.jacc.2018.01.076
[7]	Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion-an update[J]. Euro Intervention, 2020, 15(13): 1133-1180.
[8]	黄从新, 张澍, 黄德嘉, 等. 心房颤动: 目前的认识和治疗建议—2015[J]. 中华心律失常学杂志, 2015, 19(5): 321-384. doi: 10.3760/cma.j.issn.1007-6638.2015.05.001
[9]	Berti S, Santoro G, Brscic E, et al. Left atrial appendage closure using AMPLATZER^TM devices: A large, multicenter, Italian registry[J]. Int J Cardiol, 2017, 248: 103-107. doi: 10.1016/j.ijcard.2017.07.052
[10]	Korsholm K, Nielsen KM, Jensen JM, et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy[J]. Euro Intervention, 2017, 12(17): 2075-2082.
[11]	Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial[J]. Heart Rhythm, 2017, 14(9): 1302-1308. doi: 10.1016/j.hrthm.2017.05.038
[12]	Lempereur M, Aminian A, Freixa X, et al. Device-associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet[J]. Catheter Cardiovasc Interv, 2017, 90(5): E111-E121.
[13]	López-Mínguez JR, Nogales-Asensio JM, Infante De Oliveira E, et al. Long-term event reduction after left atrial appendage closure. results of the iberian registry ii[J]. Revista Espanola De Cardiologia(English Ed. ), 2019, 72(6): 449-455. doi: 10.1016/j.recesp.2018.03.020
[14]	Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF(PROTECT AF)clinical trial and the Continued Access Registry[J]. Circulation, 2011, 123(4): 417-424. doi: 10.1161/CIRCULATIONAHA.110.976449
[15]	Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study(ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)[J]. J Am Coll Cardiol, 2013, 61(25): 2551-2556. doi: 10.1016/j.jacc.2013.03.035
[16]	Saw J, Tzikas A, Shakir S, et al. Incidence and clinical impact of device-associated thrombus and peri-device leak following left atrial appendage closure with the amplatzer cardiac plug[J]. JACC Cardiovasc Interv, 2017, 10(4): 391-399. doi: 10.1016/j.jcin.2016.11.029
[17]	Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug[J]. EuroIntervention, 2016, 11(10): 1170-1179. doi: 10.4244/EIJY15M01_06
[18]	Weise FK, Bordignon S, Perrotta L, et al. Short-term dual antiplatelet therapy after interventional left atrial appendage closure with different devices[J]. Euro Intervention, 2018, 13(18): e2138-e2146.
[19]	Kaneko H, Neuss M, Weissenborn J, et al. Predictors of thrombus formation after percutaneous left atrial appendage closure using the WATCHMAN device[J]. Heart Vessels, 2017, 32(9): 1137-1143. doi: 10.1007/s00380-017-0971-x
[20]	Kaneko H, Neuss M, Weissenborn J, et al. Predictors of thrombus formation after percutaneous left atrial appendage closure using the WATCHMAN device[J]. Heart Vessels, 2017, 32(9): 1137-1143. doi: 10.1007/s00380-017-0971-x
[21]	Fauchier L, Cinaud A, Brigadeau F, et al. Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation[J]. J Am Coll Cardiol, 2018, 71(14): 1528-1536. doi: 10.1016/j.jacc.2018.01.076
[22]	Sedaghat A, Schrickel JW, Andrié R, et al. Thrombus Formation After Left Atrial Appendage Occlusion With the Amplatzer Amulet Device[J]. JACC Clin Electrophysiol, 2017, 3(1): 71-75. doi: 10.1016/j.jacep.2016.05.006
[23]	Matsushita K, Ballew SH, Wang AY, et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease[J]. Nat Rev Nephrol, 2022, 18(11): 696-707. doi: 10.1038/s41581-022-00616-6
[24]	Simard T, Jung RG, Lehenbauer K, et al. Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion[J]. J Am Coll Cardiol, 2021, 78(4): 297-313. doi: 10.1016/j.jacc.2021.04.098
[25]	Akhter HH. Introduction: who scientific group on cardiovascular disease and steroid hormone contraception[C].
[26]	Martinelli I. Thromboembolism in women[J]. Semin Thromb Hemost, 2006, 32(7): 709-715. doi: 10.1055/s-2006-951455
[27]	Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited[J]. Lancet, 2009, 373(9658): 155-166. doi: 10.1016/S0140-6736(09)60040-4
[28]	Choudhury A, Lip GY. Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice[J]. Pathophysiol Haemost Thromb, 2003, 33(5-6): 282-289. doi: 10.1159/000083815
[29]	Spronk HM, De Jong AM, Verheule S, et al. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation[J]. Eur Heart J, 2017, 38(1): 38-50. doi: 10.1093/eurheartj/ehw119
[30]	Chiasakul T, De Jesus E, Tong J, et al. Inherited thrombophilia and the risk of arterial ischemic stroke: a systematic review and meta-analysis[J]. J Am Heart Associ, 2019, 8(19): e012877. doi: 10.1161/JAHA.119.012877
[31]	唐亮, 胡豫. 《易栓症诊断与防治中国指南(2021版)》更新解读[J]. 临床血液学杂志, 2022, 35(7): 457-460.
[32]	Sedaghat A, Nickenig G, Schrickel JW, et al. Incidence, predictors and outcomes of device-related thrombus after left atrial appendage closure with the WATCHMAN device-Insights from the EWOLUTION real world registry[J]. Catheter Cardiovasc Interv, 2021, 97(7): E1019-E1024.
[33]	Plicht B, Konorza TF, Kahlert P, et al. Risk factors for thrombus formation on the Amplatzer Cardiac Plug after left atrial appendage occlusion[J]. JACC Cardiovasc Interv, 2013, 6(6): 606-613. doi: 10.1016/j.jcin.2013.02.014
[34]	Decker JM, Madder RD, Hickman L, et al. CHADS(2) score is predictive of left atrial thrombus on precardioversion transesophageal echocardiography in atrial fibrillation[J]. Am J Cardiovasc Dis, 2011, 1(2): 159-165.
[35]	Ayirala S, Kumar S, O'Sullivan DM, et al. Echocardiographic predictors of left atrial appendage thrombus formation[J]. J Am Soc Echocardiogr, 2011, 24(5): 499-505. doi: 10.1016/j.echo.2011.02.010
[36]	Yuce M, Cakici M, Davutoglu V, et al. Relationship between mean platelet volume and atrial thrombus in patients with atrial fibrillation[J]. Blood Coagul Fibrinolysis, 2010, 21(8): 722-725. doi: 10.1097/MBC.0b013e32833d6eda
[37]	Schwartz RS, Holmes DR, Van Tassel RA, et al. Left atrial appendage obliteration: mechanisms of healing and intracardiac integration[J]. JACC Cardiovasc Interv, 2010, 3(8): 870-877. doi: 10.1016/j.jcin.2010.04.017
[38]	Yu JT, Bai Y, Muenzel M, et al. Device-related thrombus after left atrial appendage closure: a 4-year retrospective analysis from a real-world setting[J]. J Am Coll Cardiol, 2017, 70(18): B258.
[39]	Grygier M, Olasinska-Wisniewska A, Trojnarska O, et al. Left atrial appendage closure-new choice for no-option patients with atrial fibrillation[J]. Minerva Cardioangiol, 2015, 63(6): 577-586.
[40]	Sharma SP, Singh D, Nakamura D, et al. Incomplete endothelialization of WatchmanTM Device: Predictors and Implications from Two Cases[J]. J Atr Fibrillation, 2019, 11(5): 2162. doi: 10.4022/jafib.2162
[41]	Prosperi-Porta G, Schnell G, Colbert J, et al. Multiple Thromboembolic Events from a Left Atrial Appendage Occlusion Device[J]. Can J Cardiol, 2018, 34(3): 342.e13-342.e15. doi: 10.1016/j.cjca.2017.12.017
[42]	Massarenti L, Yilmaz A. Incomplete endothelialization of left atrial appendage occlusion device 10 months after implantation[J]. J Cardiovasc Electrophysiol, 2012, 23(12): 1384-1385. doi: 10.1111/j.1540-8167.2012.02360.x
[43]	Freixa X, Abualsaud A, Chan J, et al. Left atrial appendage occlusion: initial experience with the Amplatzer^TM Amulet^TM[J]. Int J Cardiol, 2014, 174(3): 492-496. doi: 10.1016/j.ijcard.2014.03.154
[44]	Kubo S, Mizutani Y, Meemook K, et al. Incidence, characteristics, and clinical course of device-related thrombus after watchman left atrial appendage occlusion device implantation in atrial fibrillation patients. [J]. JACC Clin Electrophysiol, 2017, 20(3): 110.
[45]	Mill J, Agudelo V, Hion Li C, et al. Patient-specific flow simulation analysis to predict device-related thrombosis in left atrial appendage occluders[J]. REC: Interventional cardiology(English Edition), 2022, 22: 6738.
[46]	Wang Y, Di Biase L, Horton RP, et al. Left atrial appendage studied by computed tomography to help planning for appendage closure device placement[J]. J Cardiovasc Electrophysiol, 2010, 21(9): 973-982. doi: 10.1111/j.1540-8167.2010.01814.x
[47]	Nguyen A, Gallet R, Riant E, et al. Peridevice leak after left atrial appendage closure: incidence, risk factors, and clinical impact[J]. Can J Cardiol, 2019, 35(4): 405-412. doi: 10.1016/j.cjca.2018.12.022
[48]	Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF(Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation)substudy[J]. J Am Coll Cardiol, 2012, 59(10): 923-929. doi: 10.1016/j.jacc.2011.11.028
[49]	Li W, Gao R, Zhao J, et al. Safety and efficacy of different anticoagulation regimens after left atrial appendage occlusion[J]. Ann Palliat Med, 2022, 11(1): 201-209. doi: 10.21037/apm-21-3654
[50]	Bai Y, Xue X, Duenninger E, et al. Real-world survival data of device-related thrombus following left atrial appendage closure: 4-year experience from a single center[J]. Heart Vessels, 2019, 34(8): 1360-1369. doi: 10.1007/s00380-019-01364-7
[51]	Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF(WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation)trial[J]. Am Heart J, 2006, 151(5): 956-961. doi: 10.1016/j.ahj.2006.02.005
[52]	Aminian A, Schmidt B, Mazzone P, et al. Incidence, Characterization, and Clinical Impact of Device-Related Thrombus Following Left Atrial Appendage Occlusion in the Prospective Global AMPLATZER Amulet Observational Study[J]. JACC Cardiovasc Interv, 2019, 12(11): 1003-1014. doi: 10.1016/j.jcin.2019.02.003
[53]	Freixa X, Cepas-Guillen P, Flores-Umanzor E, et al. Pulmonary ridge coverage and device-related thrombosis after left atrial appendage occlusion[J]. EuroIntervention, 2021, 16(15): e1288-e1294. doi: 10.4244/EIJ-D-20-00886
[54]	Anonymous. Impact of flow dynamics on device-related thrombosis after left atrial appendage occlusion[Z], 2020-06, DOI: 10.1016/j.cjca.2019.12.036.
[55]	Hong SJ, Kim JY, Kim JB, et al. Multidetector computed tomography may be an adequate screening test to reduce periprocedural stroke in atrial fibrillation ablation: a multicenter propensity-matched analysis[J]. Heart Rhythm, 2014, 11(5): 763-770. doi: 10.1016/j.hrthm.2014.01.026
[56]	Alkhouli M, Busu T, Shah K, et al. Incidence and clinical impact of device-related thrombus following percutaneous left atrial appendage occlusion: a meta-analysis[J]. JACC Clin Electrophysiol, 2018, 4(12): 1629-1637. doi: 10.1016/j.jacep.2018.09.007
[57]	Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF Trials[J]. J Am Coll Cardiol, 2017, 70(24): 2964-2975. doi: 10.1016/j.jacc.2017.10.021
[58]	Holmes DR Jr, Alkhouli M, Reddy V. Left atrial appendage occlusion for the unmet clinical needs of stroke prevention in nonvalvular atrial fibrillation[J]. Mayo Clin Proc, 2019, 94(5): 864-874. doi: 10.1016/j.mayocp.2018.09.025
[59]	Grygier M, Olasińska-Wisniewska A, Araszkiewicz A, et al. The Watchman FLX-a new device for left atrial appendage occlusion-design, potential benefits and first clinical experience[J]. Postepy Kardiol Interwencyjnej, 2017, 13(1): 62-66.
[60]	Reddy VY, Gibson DN, Kar S, et al. Post-Approval U.S. Experience with left atrial appendage closure for stroke prevention in atrial fibrillation[J]. J Am Coll Cardiol, 2017, 69(3): 253-261. doi: 10.1016/j.jacc.2016.10.010